| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.360 | Biomarker | disease | BEFREE | Animals (<i>n</i> = 41) were divided in groups-a control group, with 8 C57/BL6 non-transgenic male mice, a diabetic group (DB), with 8 C57BLKsJ-db/db obese diabetic mice and the corresponding internal controls of 8 age-matched C57BLKsJ-db/+ mice, and a cardiac hypertrophy group (CH), with 9 FVB/NJ cα-MHC-NHE-1 transgenic mice prone to develop cardiac failure and 8 age-matched internal controls. | 31052504 | 2019 | ||||
|
0.360 | AlteredExpression | disease | BEFREE | Direct cardiac effects of SGLT2i target well-known drivers of diabetes and heart failure (elevated cardiac cytosolic [Ca<sup>2+</sup>] and [Na<sup>+</sup>], activated NHE-1, elevated inflammation, impaired vasorelaxation, and reduced AMPK activity). | 30519189 | 2018 | ||||
|
0.360 | Biomarker | disease | BEFREE | Lifetime treatment with an NHE-1 inhibitor prevented intracellular Na<sup>+</sup> overload and early death due to HF. | 28727929 | 2017 | ||||
|
0.360 | Biomarker | disease | BEFREE | Drugs used to treat diabetes mellitus may favorably affect the pathophysiological mechanisms of heart failure by inhibiting either or both NHE isoforms, and drugs used to treat heart failure may have beneficial effects on glucose tolerance and the complications of diabetes mellitus by interfering with the actions of NHE1 and NHE3. | 29038209 | 2017 | ||||
|
0.360 | Biomarker | disease | CTD_human | Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress? | 19027022 | 2009 | ||||
|
0.360 | AlteredExpression | disease | LHGDN | We conclude that activation of NHE1 is sufficient to initiate cardiac hypertrophy and heart failure mainly through activation of CaMKII-histone deacetylase pathway. | 18776042 | 2008 | ||||
|
0.360 | AlteredExpression | disease | BEFREE | We conclude that activation of NHE1 is sufficient to initiate cardiac hypertrophy and heart failure mainly through activation of CaMKII-histone deacetylase pathway. | 18776042 | 2008 | ||||
|
0.360 | Biomarker | disease | BEFREE | Inhibition of NHE1 prevented the development of heart failure in beta(1)-receptor transgenic mice. | 11964375 | 2002 |